自动化腹膜透析与连续性腹膜透析治疗终末期肾病的临床结局比较：系统评价和荟萃分析方案。

Clinical outcomes of automated versus continuous ambulatory peritoneal dialysis for end-stage kidney disease: protocol of a systematic review and meta-analysis.

机构信息

Department of Clinical Affairs, Fresenius Medical Care Shanghai Co, Beijing Branch, Beijing, China

Department of Clinical Affairs, Fresenius Medical Care Shanghai Co, Beijing Branch, Beijing, China.

出版信息

BMJ Open. 2022 Nov 2;12(11):e065795. doi: 10.1136/bmjopen-2022-065795.

DOI:10.1136/bmjopen-2022-065795

PMID:36323481

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9639101/

Abstract

INTRODUCTION

An increasing number of studies comparing automated peritoneal dialysis (APD) with continuous ambulatory peritoneal dialysis (CAPD) in clinical outcomes have been published since the publication of a systematic review and meta-analysis including three randomised controlled trials in 2007. We will conduct a systematic review and meta-analysis to explore more clinical outcomes of APD versus CAPD for end-stage kidney disease.

METHODS AND ANALYSIS

The protocol is conducted following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. Three databases-PubMed, EMBASE and the Cochrane Library-will be searched comprehensively from inception to 16 June 2022, without language restriction. Studies reporting clinical outcomes comparing APD with CAPD will be included. Two independent reviewers will screen the titles and abstracts and then obtain and assess full texts of potential relevant articles for eligibility following the inclusion and exclusion criteria. The methodological quality of included observational studies will be assessed by using the Newcastle-Ottawa Scale. The risk of bias of included randomised controlled studies will be assessed by using the Cochrane Risk of Bias tool. Relative risk for dichotomous outcomes and standard mean difference for continuous outcomes with corresponding 95% will be pooled for summary effects. Cochrane Q test and values will be used to assess heterogeneity between studies. To assess and explore the source of heterogeneity, subgroup analyses and sensitivity analyses will be conducted, and meta-regression, funnel plot and Egger's test will be performed if there are no less than 10 studies. Analyses will be performed using STATA software, V.13.0 (STATA Corporation, College Station, Texas, USA).

ETHICS AND DISSEMINATION

Ethics approval is not applicable as no personal information is collected from patients. The results will be published in a peer-reviewed journal or disseminated in relevant academic conferences.

PROSPERO REGISTRATION NUMBER

CRD42022311401.

摘要

简介

自 2007 年发表了一项包含三项随机对照试验的系统评价和荟萃分析以来，已有越来越多的研究比较了自动化腹膜透析（APD）与持续非卧床腹膜透析（CAPD）在临床结局方面的差异。我们将进行系统评价和荟萃分析，以探讨 APD 与 CAPD 治疗终末期肾病的更多临床结局。

方法和分析

本方案遵循系统评价和荟萃分析报告的首选条目（PRISMA）指南。将全面检索三个数据库——PubMed、EMBASE 和 Cochrane 图书馆，检索时间从建库至 2022 年 6 月 16 日，不限制语言。纳入比较 APD 与 CAPD 的临床结局的研究。两名独立评审员将筛选标题和摘要，然后根据纳入和排除标准获取并评估潜在相关文章的全文以确定其是否符合纳入标准。使用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）评估纳入观察性研究的方法学质量。使用 Cochrane 偏倚风险工具评估纳入随机对照研究的偏倚风险。将使用二分类结局的相对风险和连续结局的标准化均数差及其对应的 95%置信区间来汇总汇总效应。Cochrane Q 检验和 I 平方值将用于评估研究之间的异质性。为了评估和探索异质性的来源，将进行亚组分析和敏感性分析，如果有不少于 10 项研究，则进行 meta 回归、漏斗图和 Egger 检验。分析将使用 STATA 软件，V.13.0（STATA 公司，德克萨斯州，美国）进行。